Merck – AICURIS: Letermovir can be a meaningful contributor

Date: 2015-07
Pages:3
Price:

MRK collaborative agreement with Aicuris (spin-off from Bayer) gets them an interesting Phase 3 anti-infective orphan drug asset – Letermovir (Phase3, Quinazoline). for the treatment and prevention of Human Cytomegalovirus (HCMV) infection in bone marrow transplant recipients. There are 10,000 eligible patients and hence the market potential for this orphan drug would largely depend on the price that MRK can set.. Assuming a $60,000 cost of therapy and a 70% penetration in eligible patients, we forecast peak sales of $XXmillion. Cytomegalovirus (CMV) infections in recipients of allogeneic bone marrow transplants (BMTs) have historically been an important cause of morbidity and mortality, primarily because of CMV pneumonia which occurs mainly in CMV-seropositive recipients due to CMV reactivation. Existing drugs (ganciclovir) which are used for prophylaxis do not improve mortality because of the serious safety issues.
MRK collaborative agreement with Aicuris (spin-off from Bayer) gets them an interesting Phase 3 anti-infective orphan drug asset – Letermovir (Phase3, Quinazoline). for the treatment and prevention of Human Cytomegalovirus (HCMV) infection in bone marrow transplant recipients. There are 10,000 eligible patients and hence the market potential for this orphan drug would largely depend on the price that MRK can set.. Assuming a $60,000 cost of therapy and a 70% penetration in eligible patients, we forecast peak sales of $XXmillion. Cytomegalovirus (CMV) infections in recipients of allogeneic bone marrow transplants (BMTs) have historically been an important cause of morbidity and mortality, primarily because of CMV pneumonia which occurs mainly in CMV-seropositive recipients due to CMV reactivation. Existing drugs (ganciclovir) which are used for prophylaxis do not improve mortality because of the serious safety issues.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample